Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370823 · ClinicalTrials.gov registry record
A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment
A clinical trial, sponsored by Regenexx.
- Terminated
- Registry status
- 20
- Enrollment target
NCT02370823: Clinical Trial study, sponsored by Regenexx.
NCT02370823 is a clinical trial that was terminated before completion, run by Regenexx. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02370823 was terminated before completion, sponsored by Regenexx.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the levels of proteins and/or cellular components of the synovial fluid that are indicative of microenvironment phenotypes of the osteoarthritic knee compared to unilateral unaffected joints pre-injection to 6 weeks post-Regenexx® SD treatment.
Primary Outcome
A comparison of the patient temporal median change in protein concentration or percentage of cellular subpopulations from pre-injection to 6 weeks post- Regenexx SD treatment.
Interventions
- PROCEDURE Regenexx SD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-02 |
| Est. Completion | 2018-03 |
Why NCT02370823 stopped before completion
NCT02370823 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Regenexx SD is the first listed.
NCT02370823 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02370823 about?
NCT02370823 is a clinical study titled "A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment". The primary objective of this study is to determine the levels of proteins and/or cellular components of the synovial fluid that are indicative of microenvironment phenotypes of the osteoarthritic knee compared to unilateral unaffected joints pre-injection to 6 weeks post-Regenexx® SD treatment.
What is the current status of trial NCT02370823?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2015-02. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02370823?
The interventions under investigation include: Regenexx SD (PROCEDURE).
Who is sponsoring clinical trial NCT02370823?
This trial is sponsored by Regenexx, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia